# Retinitis Pigmentosa FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/retinitis-pigmentosa

> 5 upcoming FDA catalysts in retinitis Pigmentosa: sub-retinal administration of ocu400-301 (OCGN) on Feb to May 2027 (topline data readout); sub-retinal administration of ocu400-301 (OCGN) on February 2027 (primary completion); KIO-301 (KPRX) on Q3 2027 (topline data readout); KIORA PHARMACEUTICALS INC (KPRX) on August 2027 (primary completion); and 1 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2027 | [Sub-retinal administration of ocu400-301 topline data readout](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301) | OCGN | Retinitis Pigmentosa | scheduled | "NCT06388200 (A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388200)) |
| February 2027 | [Sub-retinal administration of ocu400-301 primary completion](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301) | OCGN | Retinitis Pigmentosa | scheduled | "NCT06388200 (A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Ocugen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388200)) |
| Q3 2027 | [KIO-301 topline data readout](https://sec-api.dev/pdufa/kio-301) | KPRX | retinitis pigmentosa | scheduled | "We expect the last patient, first visit in the first quarter of 2027 with topline data in the third quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/ex991-pressreleasejune3020.htm)) |
| August 2027 | [KIORA PHARMACEUTICALS INC primary completion](https://sec-api.dev/companies/kprx/catalysts) | KPRX | Retinitis Pigmentosa | scheduled | "NCT06628947 (A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Kiora Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628947)) |
| Aug to Nov 2027 | [KIORA PHARMACEUTICALS INC topline data readout](https://sec-api.dev/companies/kprx/catalysts) | KPRX | Retinitis Pigmentosa | scheduled | "NCT06628947 (A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Kiora Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628947)) |

## Drugs

- [Sub-retinal administration of ocu400-301](https://sec-api.dev/pdufa/sub-retinal-administration-of-ocu400-301) (OCGN)
- [KIO-301](https://sec-api.dev/pdufa/kio-301) (KPRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/retinitis-pigmentosa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Retinitis Pigmentosa FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/retinitis-pigmentosa

```bibtex
@misc{secapidev_indications_retinitis_pigmentosa_20261116,
  title        = {Retinitis Pigmentosa FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/retinitis-pigmentosa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_retinitis_pigmentosa_20261116","title":"Retinitis Pigmentosa FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/retinitis-pigmentosa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
